ly 255283 has been researched along with resolvin e2 in 1 studies
| Studies (ly 255283) | Trials (ly 255283) | Recent Studies (post-2010) (ly 255283) | Studies (resolvin e2) | Trials (resolvin e2) | Recent Studies (post-2010) (resolvin e2) |
|---|---|---|---|---|---|
| 54 | 0 | 15 | 17 | 1 | 12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, H; Ikeda, H; Ishimura, K; Ono, Y; Sato, Y; Shuto, S; Tansho-Nagakawa, S; Ubagai, T; Unno, Y; Watanabe, M | 1 |
1 other study(ies) available for ly 255283 and resolvin e2
| Article | Year |
|---|---|
Resolvin E1, but not resolvins E2 and E3, promotes fMLF-induced ROS generation in human neutrophils.
Topics: Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Humans; Inflammation; N-Formylmethionine Leucyl-Phenylalanine; NADPH Oxidases; Neutrophils; Onium Compounds; Reactive Oxygen Species; Receptors, Leukotriene B4; Tetrazoles | 2018 |